



REATA.

Date: July 28, 2023

Subject: Biogen to Acquire Reata Pharmaceuticals, Inc.

Dear FA Community:

Today, Reata Pharmaceuticals, Inc. and Biogen Inc. announced that they have entered into a definitive agreement, and Biogen has agreed to acquire Reata. This acquisition has the foundation in place to accelerate the delivery of SKYCLARYS® (omaveloxolone) 50 mg capsules to patients around the world.

This is a very exciting time. “Biogen’s expertise and commercial footprint make it the optimal choice to help SKYCLARYS realize its full potential,” said Warren Huff, Chairman and Chief Executive Officer of Reata. “With its clear understanding of the rare disease patient journey and existing commercial infrastructure, we believe Biogen will establish SKYCLARYS as the standard of care in the treatment of this devastating genetic disease.”

Our commitment to our patients is a high priority and we will continue to work closely and transparently with the FA community and provide a high level of engagement. Reata REACH and Biologics Specialty Pharmacy will remain in place to support and assist patients. There will be no disruptions in drug supply or access to SKYCLARYS. We will continue to operate as an independent company until further notice.

Thank you for your continued support of Reata and Reata’s programs. Reata understands the importance of providing a treatment option for individuals living with FA and we remain committed to the FA community.

Sincerely,

Seemi Khan, MD

Chief Medical Officer

Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc.
5320 Legacy Drive
Plano, TX 75024
972.865.2219
www.reatapharma.com